FINWIRES · TerminalLIVE
FINWIRES

$DHR

34 stories mentioning DHRUpdated 8d ago

Every FINWIRES story that references DHR, newest first.

Wire

Danaher Posts Mixed Q2 Results, Outlook for 2027 and Beyond Strengthened, RBC Says

Danaher's (DHR) Q2 results were mixed, with the lumpier part of its bioprocess consumables business delivering a negative surprise, while the outlook for 2027 and beyond strengthened compared with three months ago, RBC Capital Markets said in a note Tuesday.The Life Sciences segment grew 5.5% in Q2, led by improved demand for pharma and biopharma products and stability in academic and government demand. Danaher believes the demand is sustainable and lifted its Life Sciences guidance accordingly, according to the note.Bioprocess consumables and equipment orders both grew in the mid-teens percentage range in Q2, which is an important demand signal, the brokerage said.The company raised its 2026 adjusted earnings per share guidance to $8.45 to $8.60 from $8.35 to $8.55, reflecting approximately $0.07 to $0.08 from the Q2 beat and around $0.07 to $0.08 from Masimo's early close, partially offset by a slightly lower second-half outlook. The brokerage also raised its EPS forecast by the amount of the Masimo accretion, it added.RBC kept an outperform rating on Danaher and raised its price target to $215 from $200.Price: $176.56, Change: $-2.45, Percent Change: -1.37%

$DHR
Update: Wall Street Snaps 3-Day Losing Streak in Tech-Led Bounce
US Markets

Update: Wall Street Snaps 3-Day Losing Streak in Tech-Led Bounce

(Updates with market moves at the end of the day.)US equities advanced Tuesday after a three-day slump, with chip stocks lifting the technology sector, even as oil prices rose amid heightened tensions in the Middle East.The Nasdaq Composite climbed 1.3% to 25,837.21, while the S&P 500 gained 0.9% to close at 7,509.20. The Dow Jones Industrial Average rose 0.7% to 52,224.64. Barring consumer staples and communication services, all sectors ended in the green, led by tech's 2.4% gain.Micron Technology (MU) was among the best performers on the S&P 500, up 12%, while Sandisk (SNDK) surged 14%, the index's top gainer. Intel (INTC) jumped 8.6%, while Nvidia (NVDA) rose 2%, among biggest gainers on the Dow."Stock traders today have shrugged off the news from the war in favor of buying the chip makers again, presumably on the hope that the (artificial intelligence) hyperscalers, when they report (second-quarter) earnings over the next few days, will also report large capital spending plans," Macquarie said Monday in a report. "That's hoped to boost the earnings outlooks for the hardware makers."West Texas Intermediate crude oil was up 2% at $84.91 a barrel in Tuesday late-afternoon trade, while Brent rose 2.5% to $91.44.The US will hit the area of Pickaxe Mountain "probably pretty soon," news outlets reported, citing President Donald Trump. The underground facility is reportedly believed to be connected to Iran's nuclear program.Kuwait, Bahrain and Jordan intercepted Iranian aerial attacks on Tuesday, CNN reported. The US Central Command said Monday its forces had struck Iran again.Two tankers carrying Saudi crude turned back in the Red Sea as Yemen's Iran-aligned Houthis threatened to strike vessels using Saudi ports, Reuters reported.Treasury yields were higher, with the two-year rate up 4.9 basis points at 4.26% and the 10-year rate rising 3.2 basis points to 4.63%.In corporate news, 3M (MMM) raised its full-year earnings outlook as the industrial conglomerate reported second-quarter results above Wall Street's estimates. The stock jumped 7.3%, the biggest gain on the Dow.General Motors (GM) lifted its full-year profit guidance as the automaker recorded an unexpected year-over-year increase in its second-quarter revenue. The stock rose 4.9%.Danaher (DHR) slid 11%, the worst performer on the S&P 500. The medical equipment maker raised its full-year profit guidance as its fiscal second-quarter results came in stronger than expected, but it lowered the top end of its 2026 revenue growth outlook.Gold advanced 1.8% to $4,088.40 per troy ounce, while silver climbed 3.5% to $59.05 per ounce.

Dow JonesNasdaq CompositeS&P 500$AMZN$DHR$GM$INTC$MMM$MU$NVDA$SNDK
Japan

US Equity Markets Close Higher as Chipmakers Lead Tech Gains

US equity indexes ended higher on Tuesday as semiconductor stocks led gains in the technology sector amid diplomatic developments to rein in hostilities in the Middle East.* Iranian Interior Minister Eskandar Momeni arrived in Pakistan for high-level talks, news reports said. Mediators are proposing a 10-day ceasefire between Washington and Tehran, according to a Reuters report. President Donald Trump said Tehran is "desperate" to meet and talk, and threatened to attack a reported new Iranian nuclear site "very heavily," Al Jazeera reported.* Redbook US same-store sales last week rose 7.8% from a year earlier after an 8.2% increase in the previous week.* The Philadelphia Federal Reserve Bank's monthly nonmanufacturing activity index rose to 7.4 in July from minus 25.8 in June.* August West Texas Intermediate crude oil rose $1.76 to settle at $84.99 per barrel, while September Brent crude, the global benchmark, was last seen up $2.25 at $91.47.* 3M (MMM) shares rose 7.3%, the top gainer on the Dow, as the company raised its full-year earnings outlook after reporting Q2 results above Wall Street's estimates.* Danaher (DHR) shares fell 11%, the biggest drop on the S&P 500, after the company tempered full-year revenue-growth guidance even as fiscal Q2 topped estimates.

Dow JonesNasdaq CompositeS&P 500$DHR$MMM
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.4%.The iShares Biotechnology ETF (IBB) climbed 1.3%.In corporate news, Novo Nordisk (NVO) sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish drugmaker's products. Novo shares fell 0.7%, and Lilly rose 1.7%.Danaher (DHR) raised its full-year profit guidance as fiscal Q2 results came in stronger than expected. The company lowered the top end of its 2026 revenue growth outlook, and the shares fell 11%.Okyo Pharma (OKYO) shares rose 5.8%. Chairman Gabriele Cerrone increased his stake in the company to 10.9 million shares, or 20.5% of the issued shares, with the purchase of 25,000 shares at $1.40 each.MapLight Therapeutics (MPLT) is seen having meaningful upside in the ML-007 Phas2 2 schizophrenia trial readout with data expected in mid-August, UBS Securities said. MapLight shares rose 4.1%.

$DHR$LLY$MPLT$NVO$OKYO
Wire

RBC Raises Danaher Price Target to $215 From $200

Danaher (DHR) has an average rating of buy and mean price target of $241.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $178.30, Change: $-22.81, Percent Change: -11.34%

$DHR
Wire

Top Midday Decliners

Zhengye Biotechnology (ZYBT) said Tuesday it isn't aware of any material developments behind the stock's unusual trading activity.The stock slumped 71% as intraday volume topped 34.3 million shares, compared with the daily average of 2.76 million.Danaher's (DHR) shares fell 11% after the company tempered full-year revenue-growth guidance even as fiscal Q2 topped estimates.Volume topped 18.2 million shares, compared with the daily average of 4.63 million.MSCI (MSCI) shares fell 9.5% after Q2 adjusted EPS trailed estimates in a FactSet survey, and Raymond James cut its price target on the stock.Volume topped 1.35 million shares, compared with the daily average of 661,000.Price: $2.33, Change: $-5.68, Percent Change: -70.91%

$DHR$MSCI$ZYBT
Update: Equity Markets Rise Intraday in Tech-Led Advance
US Markets

Update: Equity Markets Rise Intraday in Tech-Led Advance

(Updates with latest market prices and developments.)US benchmark equity indexes were higher intraday as a rally in chip stocks drove the technology sector higher, even as tensions between the US and Iran remained high.The Nasdaq Composite was up 1.4% at 25,854.7 after midday Tuesday, while the S&P 500 advanced 0.9% to 7,508.7. The Dow Jones Industrial Average rose 0.9% to 52,280.4. Most sectors were in the green, led by tech's 2.2% gain, while consumer staples led the laggards.Micron Technology (MU) was among the best performers on the S&P 500, up nearly 13%, along with Sandisk (SNDK), which also surged almost 13%. Intel (INTC) jumped 8.1%, while Nvidia (NVDA) also moved higher."Stock traders today have shrugged off the news from the war in favor of buying the chip makers again, presumably on the hope that the (artificial intelligence) hyperscalers, when they report (second-quarter) earnings over the next few days, will also report large capital spending plans," Macquarie said Monday in a report. "That's hoped to boost the earnings outlooks for the hardware makers."West Texas Intermediate crude oil was up 2.4% at $85.25 a barrel intraday, while Brent rose 2.1% to $91.07.Kuwait, Bahrain and Jordan intercepted Iranian aerial attacks on Tuesday, CNN reported. The US Central Command said Monday its forces had struck Iran again.Two tankers carrying Saudi crude turned back in the Red Sea as Yemen's Iran-aligned Houthis threatened to strike vessels using Saudi ports, Reuters reported.Treasury yields were higher intraday, with the two-year rate up 3.8 basis points at 4.25% and the 10-year rate rising 2.8 basis points to 4.63%.In corporate news, 3M (MMM) raised its full-year earnings outlook as the industrial conglomerate reported second-quarter results above Wall Street's estimates. The stock was up 7.5% intraday, the biggest gain on the Dow.General Motors (GM) lifted its full-year profit guidance as the automaker recorded an unexpected year-over-year increase in its second-quarter revenue. The stock rose 5.4%.Danaher (DHR) slid 12%, the worst performer on the S&P 500. The medical equipment maker raised its full-year profit guidance as its fiscal second-quarter results came in stronger than expected, but it lowered the top end of its 2026 revenue growth outlook.Gold advanced 1.6% to $4,079.80 per troy ounce, while silver climbed 3.6% to $59.12 per ounce.

Dow JonesNasdaq CompositeS&P 500$DHR$GM$INTC$MMM$MU$NVDA$SNDK
Sectors

Sector Update: Healthcare Stocks Advance Tuesday Afternoon

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.1%.The iShares Biotechnology ETF (IBB) gained 1%.In corporate news, Novo Nordisk (NVO) on Tuesday sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish drugmaker's products. Novo shares were down 0.6%, and Lilly was rising 1.2%.Danaher (DHR) raised its full-year profit guidance on Tuesday as its fiscal Q2 results came in stronger than expected, but the company lowered the top end of its 2026 revenue growth outlook. Its shares fell past 12%.Okyo Pharma (OKYO) shares jumped past 8% after it said Chairman Gabriele Cerrone has increased his stake in the company to 10.9 million shares, or 20.5% of the company's issued share capital, with the purchase of 25,000 ordinary shares at $1.40 per share.

$DHR$LLY$NVO$OKYO
Wire

Evercore ISI Adjusts Price Target on Danaher to $205 From $230

Danaher (DHR) has an average rating of buy and mean price target of $241.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $174.20, Change: $-26.91, Percent Change: -13.38%

$DHR
Wire

Top Midday Stories: 3M Shares Rise on Strong Guidance; Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising

All three major US stock indexes were up in late-morning trading Tuesday, as investors focused on some strong corporate earnings reports.In company news, 3M (MMM) reported Q2 adjusted earnings Tuesday of $2.40 per share, up from $2.16 a year earlier and above the FactSet consensus analyst estimate of $2.25. Second-quarter revenue was $6.5 billion, up from $6.34 billion a year ago and above the FactSet consensus of $6.40 billion. For fiscal 2026, the company expects adjusted EPS of $$8.80 to $8.95, up from its previous outlook of $8.50 to $8.70 and above the FactSet consensus of $8.74. 3M shares were up 8.7% around midday.Novo Nordisk (NVO) said Tuesday it filed a lawsuit against Eli Lilly (LLY) in the US District Court for the District of New Jersey alleging the drugmaker's advertising for Zepbound and Mounjaro violates federal and state false advertising and unfair competition laws. Novo shares were down 0.3%, while Lilly shares were up 1.3%.Utz Brands (UTZ) has entered into a definitive agreement through which Intersnack Group will acquire all of its outstanding common stock for $14.25 per share in cash and take it private, the companies said Tuesday. The price represents an enterprise value of about $2.9 billion and a 91% premium over Utz's closing price on July 20, the companies said. The deal is expected to close in Q4, subject to regulatory and other conditions, they said. Utz shares were up 89.5%.Danaher (DHR) reported Q2 adjusted net earnings Tuesday of $1.94 per diluted share, up from $1.80 a year earlier and above the FactSet consensus of $1.84. Second-quarter sales were $6.27 billion, up from $5.94 billion a year ago and above the FactSet consensus of $6.11 billion. For full-year 2026, the company raised its adjusted diluted EPS guidance to $8.45 to $8.60 from $8.35 to $8.55. Analysts polled by FactSet expect $8.45. Danaher shares were down $14.1%.General Motors (GM) reported Q2 adjusted diluted EPS Tuesday of $3.57, up from $2.53 a year earlier and above the FactSet consensus of $3.19. Second-quarter revenue was $48.03 billion, up from $47.12 billion a year ago and above the FactSet consensus of $47.01 billion. For 2026, the company expects adjusted EPS of $12 to $14, compared with the FactSet consensus of $12.97. GM shares were up 4.0%.MSCI (MSCI) reported Q2 adjusted EPS of $4.94, up from $4.17 a year earlier but below the FactSet consensus of $4.99. Second-quarter operating revenue was $867 million, up from $772.7 million a year ago but below the FactSet consensus of $870.7 million. MSCI shares were down 8.7%.Price: $49.45, Change: $-0.16, Percent Change: -0.33%

$DHR$GM$LLY$MMM$MSCI$NVO$UTZ
Danaher Lifts Full-Year Profit Outlook Following Second-Quarter Beat, Tempers Sales Guidance
US Markets

Danaher Lifts Full-Year Profit Outlook Following Second-Quarter Beat, Tempers Sales Guidance

Danaher raised its full-year profit guidance on Tuesday as its fiscal second-quarter results came in stronger than expected, but the company lowered the top end of its 2026 revenue growth outlook.The medical equipment maker now expects adjusted per-share earnings of $8.45 to $8.60 for full-year 2026, up from its previous guidance of $8.35 to $8.55. The company said the updated outlook takes into account its strong second-quarter profit performance and the earlier-than-anticipated completion of its acquisition of health technology company Masimo. Analysts in a FactSet poll are looking for $8.45, up from last year's EPS of $7.80.Danaher is now guiding full-year core revenue to increase 3% to 4%, lowering the top end of the range from 6%. For the ongoing quarter, the company projects core sales growth of 2% to 3% year over year, indicating a possible sequential slowdown.The third-quarter outlook "includes an approximately 250 basis point year-over-year headwind from respiratory testing," Chief Executive Rainer Blair said at an earnings conference call, according to a FactSet transcript.Shares of Danaher were down more than 12% in Tuesday morning trade. The stock has slid 22% so far this year."Our updated outlook reflects higher anticipated core revenue growth in our life sciences segment as we expect these markets to recover faster than our initial expectations, offset by a slightly more conservative outlook for bioprocessing given some of the customer-driven timing dynamics we saw in the second quarter," Blair said.For the quarter ended June 26, adjusted EPS rose to $1.94 from $1.80 a year earlier, exceeding the consensus of $1.84. Overall sales grew 5.5% to $6.27 billion, while analysts projected $6.11 billion.Core sales in the second quarter increased 3% amid growth across all three segments led by life sciences."Our life sciences businesses delivered their strongest quarter in several years," Blair told analysts. "Diagnostics continued to perform well, and while customer project timing impacted bioprocessing revenue, underlying order trends remained robust."Price: $177.27, Change: $-23.85, Percent Change: -11.86%

$DHR
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Tuesday

Healthcare stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.9% lower and the iShares Biotechnology ETF (IBB) up 0.3%.Novartis (NVS) stock was up more than 3% after the company reported Q2 core earnings and net sales that topped analysts' expectations.Danaher (DHR) shares were down more than 15% even after the company posted higher Q2 adjusted net earnings and sales, and raised its 2026 adjusted EPS guidance.Agios Pharmaceuticals (AGIO) shares were down more than 12% after the company said it will halt development of its oral medicine, tebapivat, for sickle cell disease after a Phase 2 study failed to demonstrate a distinct clinical profile.

$AGIO$DHR$IBB$NVS$XLV
Asia Markets

Update: Potential Middle East Ceasefire Lifts US Equity Futures Pre-Bell

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were higher pre-bell Tuesday as traders digested new efforts by mediators to put peace talks between the US and Iran back on track.Dow Jones Industrial Average futures were 0.3% higher, S&P 500 futures were up 0.4%, and Nasdaq futures were 1.3% higher.The US Central Command said it completed another round of attacks against Iran on Monday evening, as news reports said Tuesday that Iran-backed Houthis in Yemen are planning a naval blockade on Saudi Arabia.Mediators are proposing a 10-day ceasefire between the two nations, giving hope that hostilities may de-escalate. Iranian Interior Minister Eskandar Momeni has asked Pakistan to resume its mediation role in the conflict and traveled to Islamabad for further discussions, according to a Reuters report.Traders took note of the latest round of earnings, with Novartis (NVS) reporting lower core earnings and higher net sales for Q2.Interactive Brokers Group (IBKR) is expected to report its Q2 financial results after the market closes. Analysts polled by FactSet expect adjusted earnings of $0.64 per share and revenue of $1.8 billion.Oil prices were higher, with front-month global benchmark North Sea Brent crude up 1.8% at $90.83 per barrel and US West Texas Intermediate crude 1.8% higher at $83.97 per barrel.The economic calendar is vacant.In other world markets, Japan's Nikkei closed 3.3% higher, Hong Kong's Hang Seng ended flat, and China's Shanghai Composite finished 1.8% higher. Meanwhile, the UK's FTSE 100 was up 0.1%, and Germany's DAX index was 0.1% higher in Europe's early afternoon session.In equities, Micron Technology (MU) and SK Hynix (SKHY) stocks were up 5.6% and 5.4%, respectively, as part of a broader rebound in technology-related stocks. Novartis shares rose 3.2% after the company reported Q2 core earnings and net sales that surpassed analysts' consensus estimates. 3M (MMM) stock was up 6% after the company posted a Q2 beat for adjusted earnings and revenue, as well as raised its fiscal 2026 adjusted earnings outlook.On the losing side, Charles Schwab (SCHW) stock was down 1.3% despite the company's Q2 adjusted earnings and net revenue exceeding analysts' estimates. Danaher (DHR) shares dropped 13% despite the company reporting Q2 earnings and revenue above expectations, and raising its 2026 earnings guidance.

Dow JonesNasdaq CompositeS&P 500$DHR$IBKR$MMM$MU$NVS$SCHW$SKHY
Stocks Rise Pre-Bell as Investors Await More Earnings, Monitor Middle East Developments
US Markets

Stocks Rise Pre-Bell as Investors Await More Earnings, Monitor Middle East Developments

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corporate earnings and assess the latest developments in the Middle East.The S&P 500 rose 0.5%, the Dow Jones Industrial Average gained 0.3% and the Nasdaq added 1.3% in premarket activity. The indexes closed the previous trading session lower.Charles Schwab (SCHW), Danaher (DHR), 3M (MMM), Northrop Grumman (NOC), General Motors (GM), D.R. Horton (DHI), Genuine Parts (GPC) and Hasbro (HAS) are some of the major companies scheduled to release their latest financial results before the bell.Interactive Brokers (IBKR) and Alaska Air (ALK) post earnings after the markets close, among others."The reporting calendar is shifting beyond the first wave of money-center banks toward large tech, industrial and consumer names," Tigress Financial said in a note Monday. "The narrative will increasingly focus on whether (artificial intelligence) platforms, cloud providers and key cyclicals can match the strong bank prints without sparking renewed worries about margins or demand."The UK Maritime Trade Operations said Tuesday it has received multiple reports that a tanker was struck by an unknown projectile in the Strait of Hormuz. The US Central Command said Monday its forces completed their latest round of strikes against Iran.A senior official from Tehran told Reuters that mediators have forwarded a 10-day ceasefire proposal to Iran in an attempt to revive the interim deal reached with the US last month. Houthi militants in Yemen on Monday declared a maritime embargo against Saudi Arabia, effective immediately, CNBC reported, citing Yemen News Agency.President Donald Trump said Monday that "every time Iran kills an American soldier they will pay for that killing many times over." The US recently confirmed the passing of at least three service members during recent fighting with Iran.West Texas Intermediate crude oil edged up 0.3% to $83.49 a barrel before the opening bell, while Brent increased 0.4% to $89.60.Trump signed three proclamations on Monday to impose 50% tariffs on the imports of motor vehicles, alcohol and dairy products from Canada, in response to its "discriminatory treatment of American products," according to the White House. The tariffs are set to come into effect after 30 days.Treasury yields were moving downwards in premarket action, with the two-year rate retreating 1.9 basis points to 4.2% and the 10-year rate off 0.4 basis points to 4.59%.Gold advanced 1.4% to $4,073 per troy ounce, while bitcoin climbed 1.9% to $66,296.

Dow JonesNasdaq CompositeS&P 500$ALK$DHI$DHR$GM$GPC$HAS$IBKR$MMM$NOC$SCHW
Asia Markets

Tech Rebound Boosts Wall Street Pre-Bell; Asia, Europe Up

Wall Street futures pointed higher pre-bell Tuesday as tech traders toggled risk-on switches despite ongoing Persian Gulf hostilities.In the futures, the S&P 500 rose 0.5%, the Nasdaq inclined 1.4% and the Dow Jones was up 0.4%.The VanEck Semiconductor ETF (SMH) traded up 3.3% pre-bell.West Texas Intermediate crude oil traded up 1% at $83.29 a barrel in morning hours.Asian exchanges traded higher overnight on tech sector rallies, led by a 3.3% rise in Tokyo's Nikkei 225, a 3.6% lift on Seoul's semiconductor-heavy KOSPI index, and a 4.2% rise on Taiwan TWSE index.European bourses tracked moderately north midday on the continent.Danaher (DHR) fell 10.2% pre-bell despite the science and healthcare products enterprise reporting Q2 earnings and revenue above expectations, and raising its 2026 earnings guidance.The economic calendar is vacant.In premarket action, Bitcoin traded at $66,334, and 10-year US Treasuries offered 4.59%. Spot gold commanded $4,068 an ounce.

Dow JonesNasdaq CompositeS&P 500$DHR
Wire

Baird Adjusts Price Target on Danaher to $251 From $245, Maintains Outperform Rating

Danaher (DHR) has an average rating of buy and mean price target of $241.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $199.94, Change: $+1.01, Percent Change: +0.51%

$DHR
Wire

Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says

Danaher (DHR) could see about 6% revenue growth in 2027, driven by a rebound in bioprocess demand trends and improving end markets, RBC Capital Markets said.RBC's channel checks indicate robust demand trends for bioprocess consumables and expanding equipment funnels, according to the note. This positions Danaher to benefit from the sector recovery as bioprocessing represents more than 25% of the company's revenue, the investment firm said in a Thursday note.Danaher is also working to close menu gaps in its Beckman Coulter business and sees continued improvement in its molecular diagnostics segment amid a recovering underlying diagnostics market. The company could see further growth upside from its Masimo (MASI) acquisition, which is expected to close in the second half of 2026, RBC added.RBC Capital Markets resumed coverage on Danaher, with an outperform rating and a $200 price target.Shares of Danaher were down 1.1% in Friday afternoon trading.Price: $162.75, Change: $-1.79, Percent Change: -1.09%

$DHR
Danaher Set for Growth Reacceleration Amid Strong Bioprocessing Trends, RBC Says
US Markets

Danaher Set for Growth Reacceleration Amid Strong Bioprocessing Trends, RBC Says

Danaher (DHR) is poised for growth reacceleration amid strong bioprocessing demand trends in the broader tools industry, RBC Capital Markets said in a client note emailed Friday.The brokerage's channel checks consistently point to strong demand trends for bioprocess consumables and expanding equipment funnels. Bioprocessing represents more than 25% of Danaher's revenue and is the "healthiest end market" across the tools industry, according to RBC."A sustained bioprocess rebound (supported by incremental equipment growth), the lapping of idiosyncratic headwinds, and progressive end-market improvement put 6% revenue growth within reach for 2027," RBC analyst Dan Leonard said in the note. The expected completion of the company's Masimo (MASI) acquisition in the second half also provides additional upside to the growth profile, the brokerage added.In February, Danaher agreed to acquire health technology company Masimo in a deal worth about $9.9 billion to boost its diagnostics portfolio. The Masimo acquisition is expected to be accretive to growth and margins, while RBC sees "meaningful white space" for further consolidation in the life sciences segment.The medical equipment maker's underlying diagnostics business continues to improve, apart from some structural challenges in China, RBC said."We see continued runway for Danaher to deploy capital inorganically in life sciences and diagnostics," Leonard said.Last month, Danaher reported first-quarter adjusted earnings of $2.06 per share, up from $1.88 a year earlier. Revenue increased 3.5% to $5.95 billion. At the time, the company said it expected its full-year adjusted EPS to be in a range of $8.35 to $8.55, reflecting a higher top end versus the previous guidance of $8.50.RBC has an outperform rating on Danaher's stock with a price target of $200.Price: $163.60, Change: $-0.94, Percent Change: -0.57%

$DHR
Wire

Argus Adjusts Price Target on Danaher to $230 From $265, Maintains Buy Rating

Danaher (DHR) has an average rating of buy and mean price target of $248, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $177.19, Change: $-1.38, Percent Change: -0.77%

$DHR
Wire

Morgan Stanley Cuts Price Target on Danaher to $255 From $270

Danaher (DHR) has an average rating of buy and mean price target of $248.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $185.92, Change: $-8.62, Percent Change: -4.43%

$DHR

Showing 1-20 of 34

Track with the FINWIRES app suite

FolioX
FolioX
Track DHR in your portfolio
WheelAI
WheelAI
Analyze DHR options with the wheel strategy
StockInsider
StockInsider
See market sentiment on DHR